FGF11 Antibody

What is FGF11 and how does it differ from other FGFs?

FGF11 belongs to the intracellular FGF (iFGF) subfamily (FGF11-FGF14), which distinguishes it from canonical and endocrine FGFs. Unlike secreted FGFs that signal through FGF receptors (FGFRs), FGF11 lacks a classical secretory signal and instead contains a bipartite nuclear localization signal in its N-terminus . FGF11 functions intracellularly in an FGFR-independent manner despite retaining the ability to bind heparin with high affinity like other FGFs . This fundamental difference in localization and signaling mechanism makes FGF11 functionally distinct from classical growth factors.

What are the primary biological roles of FGF11?

FGF11 is primarily expressed in the nervous system, particularly in the developing and adult brain with notable expression in the cerebral cortex, hippocampus, and cerebellum . Research indicates FGF11 is likely involved in:

• Nervous system development and function

• Hypoxia response through direct interaction with HIF-1α

• Tumor cell immune escape mechanisms by promoting T cell exhaustion

• Potential role as a prognostic biomarker in certain cancers

What is the molecular weight of FGF11 and how can it be identified in samples?

FGF11 has a predicted molecular weight of approximately 25 kDa, which aligns with the observed band size in Western blot analyses using validated antibodies . In immunohistochemical applications, FGF11 typically shows cytoplasmic or nuclear staining patterns depending on the cellular context and activation state. Human placental tissue can serve as a positive control for FGF11 detection .

What are the optimal conditions for FGF11 antibody use in immunohistochemistry?

For successful immunohistochemical detection of FGF11 in tissue samples, researchers should follow this optimized protocol:

FGF11 IHC Protocol:

• Fix tissues in 10% formalin for 24 hours

• Process tissues using standard procedures and embed in paraffin

• Section tissues at 3 μm thickness

• Perform heat-induced antigen retrieval with EDTA buffer (pH 9.0) for 20 minutes

• Block endogenous peroxidase with hydrogen peroxide for 10 minutes

• Incubate with anti-FGF11 antibody (e.g., MM0282-6J20, ab89713) at 1:100 dilution for 200 minutes

• Apply HRP-conjugated polymer detection system (e.g., Leica DS9800)

• Develop with DAB for 8 minutes and counterstain with hematoxylin

For scoring FGF11 expression, the following scale has been validated:

• Score 0: 0-5% positive cells

• Score 1: 6-10% positive cells

• Score 2: 11-50% positive cells

• Score 3: 51-100% positive cells

What applications are FGF11 antibodies validated for?

The following table summarizes validated applications for FGF11 antibodies:

What controls should be included when using FGF11 antibodies?

To ensure experimental rigor when working with FGF11 antibodies, researchers should include:

• Positive controls:

  • Human placental tissue (validated expression)

  • Brain tissue sections (cerebral cortex, hippocampus, cerebellum)

  • Cell lines with known FGF11 expression

• Negative controls:

  • Primary antibody omission

  • Isotype-matched control antibody

  • FGF11-knockdown cells/tissues (if available)

• Technical controls:

  • Loading controls for Western blot (e.g., β-actin, GAPDH)

  • Internal tissue controls for IHC (tissues with known expression patterns)

How can FGF11 antibodies be used to investigate tumor immune microenvironment?

Analysis of the relationship between FGF11 and the immune microenvironment revealed that FGF11 expression inversely correlates with infiltration of six types of immune cells. Particularly notable was its negative correlation with various functional T cell populations, including Th1, Th1-like, regulatory T cells (Tregs), and resting Tregs . This suggests FGF11 may contribute to tumor progression by promoting T cell exhaustion.

Research applications:

• Use FGF11 antibodies for multiplex immunofluorescence to simultaneously visualize FGF11 expression and immune cell markers

• Correlate FGF11 expression levels with T cell exhaustion markers in clinical samples

• Investigate mechanistic pathways by which FGF11 modulates T cell function in co-culture experiments

What is known about FGF11's role in hypoxia response, and how can researchers investigate this?

FGF11 has been identified as a hypoxia-inducible factor that directly interacts with HIF-1α to enhance its stability . This creates a positive feedback loop wherein hypoxia induces FGF11 expression, which then reinforces hypoxia responses by stabilizing HIF-1α protein.

Experimental approach for studying FGF11-HIF-1α interaction:

• Co-immunoprecipitation using FGF11 antibodies to pull down associated proteins, followed by HIF-1α detection

• Protein stability assays comparing HIF-1α half-life in FGF11-knockdown versus control cells

• Ubiquitination assays to assess how FGF11 affects HIF-1α ubiquitination and proteasomal degradation

Notably, manipulation of FGF11 levels affects HIF-1α protein without altering its mRNA expression, indicating post-transcriptional regulation . This suggests FGF11 antibodies could be valuable tools for dissecting the molecular mechanisms of hypoxia response in various pathological conditions, including cancer.

Can FGF11 antibodies be used to develop diagnostic or prognostic assays?

Emerging evidence suggests FGF11 may serve as a biomarker for various cancers. In lung adenocarcinoma, high FGF11 expression correlates with poor prognosis, making it a potential prognostic marker . Similarly, IHC studies are exploring FGF11's utility as a predictive marker for breast cancer .

Considerations for biomarker development:

• Standardize IHC protocols using validated FGF11 antibodies

• Establish clear scoring criteria (e.g., percentage of positive cells and staining intensity)

• Correlate expression with clinicopathological features and patient outcomes

• Validate findings across multiple patient cohorts

Researchers developing such assays should consider FGF11's differential expression in cancer versus normal tissues and its correlations with specific molecular pathways (e.g., hypoxia signaling, immune modulation) to enhance the clinical utility of these biomarkers.

What factors might affect FGF11 antibody specificity and detection sensitivity?

Several factors can impact the performance of FGF11 antibodies:

• Fixation methods:

  • Overfixation can mask epitopes

  • Different fixatives may differentially preserve FGF11 structure

  • Optimal fixation: 10% neutral-buffered formalin for 24 hours

• Antigen retrieval:

  • EDTA-based retrieval (pH 9.0) is recommended over citrate buffer

  • Retrieval duration should be optimized (20 minutes typical)

  • Incomplete retrieval may yield false-negative results

• Cross-reactivity concerns:

  • The FGF family shares structural similarities

  • Validate antibodies against other FGF family members

  • Consider using antibodies targeting unique regions of FGF11

• Detection methods:

  • Signal amplification systems vary in sensitivity

  • HRP-conjugated polymer detection systems show good results for FGF11

  • Consider tyramide signal amplification for low-abundance detection

How should researchers interpret FGF11 data in relation to hypoxia studies?

When studying FGF11 in hypoxia-related research, consider these interpretation guidelines:

• Temporal dynamics:

  • FGF11 induction occurs following hypoxia exposure

  • Examine both early (HIF-1α stabilization) and late (FGF11 induction) timepoints

  • Consider potential feedback loops where FGF11 further enhances HIF-1α stability

• Protein vs. mRNA analysis:

  • FGF11 affects HIF-1α at the protein level without altering mRNA

  • Ubiquitination assays show FGF11 acts upstream of proteasomal degradation

  • Both protein and transcript levels should be analyzed for comprehensive understanding

• Functional significance:

  • Correlate FGF11 levels with downstream hypoxia-responsive genes

  • Assess biological outcomes of FGF11 manipulation under hypoxic conditions

  • Consider cell-type specific effects given FGF11's tissue-specific expression patterns

What technical challenges might arise when using FGF11 antibodies for endogenous protein detection?

Detecting endogenous FGF11 presents several technical challenges:

• Low endogenous expression:

  • FGF11 may be expressed at low levels in many cell types

  • Consider enrichment approaches (e.g., immunoprecipitation before Western blot)

  • Use highly sensitive detection methods (chemiluminescent substrates, amplified fluorescence)

• Subcellular localization:

  • As an intracellular FGF, proper sample preparation is crucial

  • Nuclear localization signal may direct FGF11 to nucleus under certain conditions

  • Subcellular fractionation may be necessary to fully characterize expression

• Post-translational modifications:

  • Consider whether post-translational modifications affect antibody recognition

  • Phosphorylation states may change during experimental treatments

  • Use multiple antibodies targeting different epitopes when possible

• Validation strategies:

  • Use siRNA/shRNA knockdown to confirm band specificity

  • Compare results across multiple detection methodologies

  • Include positive control samples with known FGF11 expression (e.g., placenta, brain tissues)

What emerging research areas might benefit from FGF11 antibody applications?

Several promising research areas could benefit from FGF11 antibody applications:

• Cancer immunotherapy:

  • Investigating FGF11's role in T cell exhaustion and tumor immune escape

  • Developing combination therapies targeting FGF11 in immunoresistant tumors

  • Using FGF11 as a predictive biomarker for immunotherapy response

• Hypoxia-related pathologies:

  • Exploring FGF11-HIF-1α interaction in ischemic diseases

  • Targeting FGF11 to modulate hypoxia response in cancer

  • Studying FGF11 in adaptation to hypoxic environments

• Neurodevelopment and neurodegeneration:

  • Given FGF11's expression in the nervous system , investigating its roles in:

    • Neural differentiation and circuit formation

    • Neuronal survival under stress conditions

    • Potential involvement in neurodegenerative processes

How might antibody-based targeting of FGF11 be developed for therapeutic applications?

While current research focuses primarily on FGF11 as a biomarker, future therapeutic strategies might include:

• Intracellular antibody fragments (intrabodies):

  • Developing cell-penetrating antibody fragments targeting FGF11

  • Disrupting FGF11-HIF-1α interaction to modulate hypoxia response

  • Impairing FGF11's role in tumor immune evasion

• Conjugated antibody strategies:

  • Antibody-drug conjugates for FGF11-expressing cancer cells

  • Nanoparticle-conjugated anti-FGF11 for intracellular delivery

  • Bifunctional antibodies redirecting cellular machinery to degrade FGF11

• Combination approaches:

  • Pairing FGF11 targeting with immune checkpoint inhibitors

  • Combining with hypoxia-targeted therapies

  • Synergizing with conventional cancer treatments

Understanding FGF11's precise mechanisms of action in different biological contexts will be crucial for developing such therapeutic approaches.